The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
February 29, 2016
Olaparib (Lynparza) for Advanced Ovarian Cancer (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Olaparib (Lynparza) for Advanced Ovarian Cancer (online only)
February 29, 2016 (Issue: 1489)
The FDA has approved the oral poly (ADP-ribose) polymerase
(PARP) inhibitor olaparib (Lynparza – Astra-Zeneca) as monotherapy for treatment of women with
advanced ovarian cancer who have BRCA1/2 germline
mutations and have received at least 3...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.